Drotrecogin Alfa (Activated): A Viewpoint by Marcel Levi

ISSN： 0012-6667

Source： Drugs, Vol.62, Iss.4, 2002-04, pp. : 631-632

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drotrecogin Alfa (Activated)

By Lyseng-Williamson K.A. Perry C.M.

Drugs, Vol. 62, Iss. 4, 2002-04 ,pp. : 617-630

Adis International

Access to resources Recommend Favorite

Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis

By Frampton J.E. Foster R.H.

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 445-476

Adis International

Access to resources Recommend Favorite

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

By McCoy Christopher

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 625-637

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Drotrecogin Alfa (Activated) in the Treatment of Sepsis

By Daniel De Backer

Drug Safety, Vol. 30, Iss. 11, 2007-01 ,pp. : 995-1010

Adis International

Access to resources Recommend Favorite

An Evaluation of the Cost Effectiveness of Drotrecogin Alfa (Activated) Relative to the Number of Organ System Failures

By Betancourt M.

PharmacoEconomics, Vol. 21, Iss. 18, 2003-01 ,pp. : 1331-1340

Adis International

Access to resources Recommend Favorite